Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Cash (2018 - 2025)

Bicycle Therapeutics' Change in Cash history spans 8 years, with the latest figure at -$20.2 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 77.72% year-over-year to -$20.2 million; the TTM value through Dec 2025 reached -$251.4 million, down 171.18%, while the annual FY2025 figure was -$251.4 million, 171.18% down from the prior year.
  • Change in Cash reached -$20.2 million in Q4 2025 per BCYC's latest filing, up from -$73.1 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $504.4 million in Q2 2024 to a low of -$86.5 million in Q1 2025.
  • Average Change in Cash over 5 years is $24.6 million, with a median of -$21.2 million recorded in 2022.
  • Peak YoY movement for Change in Cash: tumbled 1319.67% in 2022, then skyrocketed 2154.88% in 2023.
  • A 5-year view of Change in Cash shows it stood at $179.2 million in 2021, then plummeted by 112.46% to -$22.3 million in 2022, then tumbled by 104.63% to -$45.7 million in 2023, then soared by 75.16% to -$11.3 million in 2024, then crashed by 77.72% to -$20.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Change in Cash are -$20.2 million (Q4 2025), -$73.1 million (Q3 2025), and -$71.5 million (Q2 2025).